New drug targets inflammation in Hard-to-Treat Behçet's disease
NCT ID NCT07634848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a drug called ivarmacitinib in people with Behçet's disease who have not improved with standard treatments. Ivarmacitinib blocks a key inflammation pathway (JAK-STAT) to reduce symptoms. Participants take the drug daily for 24 weeks, and researchers monitor their response and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivarmacitinib
What this could lead to
If successful, this could offer a new treatment option for people with Behçet's disease who do not respond to current therapies.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group. Results may not apply to all patients, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHCET'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••